Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published 10 November 2010 Volume 2010:6 Pages 1023—1037


Review by Single-blind

Peer reviewer comments 2

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other article by this author:

Lipid-modifying therapy in the elderly

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M

Vascular Health and Risk Management 2015, 11:251-263

Published Date: 14 May 2015

Readers of this article also read:

Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer

Chen YY, Wang LW, Wang SY, Wu BB, Wang ZM, Chen FF, Xiong B

OncoTargets and Therapy 2015, 8:2033-2043

Published Date: 4 August 2015

Stemness and plasticity of lung cancer cells: paving the road for better therapy

Luo JD, Zhou XF, Yakisich JS

OncoTargets and Therapy 2014, 7:1129-1134

Published Date: 23 June 2014

Management of pediatric corneal limbal dermoids

Pirouzian A

Clinical Ophthalmology 2013, 7:607-614

Published Date: 28 March 2013


Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)

Bhurayanontachai P, Ratanasukon M, Jirarattanasopa P

Clinical Ophthalmology 2011, 5:567-572

Published Date: 6 May 2011

Role of olmesartan in combination therapy in blood pressure control and vascular function

Carlos M Ferrario, Ronald D Smith

Vascular Health and Risk Management 2010, 6:701-709

Published Date: 9 August 2010

Practical recommendations for treatment of hypertension in older patients

Philip A Kithas, Mark A Supiano

Vascular Health and Risk Management 2010, 6:561-569

Published Date: 29 June 2010

Molecular markers of susceptibility to ocular toxoplasmosis, host and guest behaving badly

Adriana Lima Vallochi, Anna Carla Goldberg, Angela Falcai, Rajendranath Ramasawmy, Jorge Kalil, et al

Clinical Ophthalmology 2008, 2:837-848

Published Date: 5 December 2008